Merck’s investigational oral PCSK9 inhibitor, Enlicitide, lowered low‑density lipoprotein cholesterol by 64.6% in the Phase 3 CORALreef AddOn trial, which evaluated the drug added to background statin therapy over eight weeks. The result, the highest LDL‑lowering effect reported for an oral PCSK9 agent, establishes Enlicitide as the first oral macrocyclic peptide PCSK9 inhibitor to achieve clinically meaningful and statistically significant LDL‑C reduction.
The 64.6% reduction is a landmark for the cholesterol‑lowering market, which has been dominated by injectable therapies. By delivering antibody‑like efficacy orally, Enlicitide could capture a large share of the high‑margin market and accelerate its regulatory and commercial trajectory. The data also reinforce Merck’s cardio‑pulmonary strategy and its goal of diversifying revenue streams beyond the upcoming Keytruda patent cliff.
"Enlicitide, designed to deliver antibody‑like efficacy, is the first oral macrocyclic peptide PCSK9 inhibitor with clinically meaningful and statistically significant LDL‑C lowering in Phase 3 trials," said Dr. Dean Y. Li, president of Merck Research Laboratories. Lead author Alberico Catapano added, "Results from CORALreef AddOn demonstrate that enlicitide can significantly reduce LDL‑C compared to established oral non‑statin treatment options, reinforcing the practice‑changing potential of an oral PCSK9 inhibitor."
The FDA has selected Enlicitide for the Commissioner's National Priority Voucher, positioning the drug for accelerated review. The strong Phase 3 data also support Merck’s pipeline diversification beyond Keytruda, providing a potential multi‑billion‑dollar franchise that could offset the company’s future revenue decline as Keytruda’s patent expires.
BMO Capital Markets described the announcement as a "multi‑billion‑dollar opportunity," and investors view the data as a positive catalyst for Enlicitide’s future approval and market adoption.
Enlicitide’s performance places it ahead of other oral candidates, such as AstraZeneca’s AZD0780, and offers a distinct advantage over existing injectable PCSK9 inhibitors like Repatha and Praluent. The oral route could improve patient adherence and broaden the drug’s commercial appeal, positioning Merck to capture a significant portion of the projected $28 billion PCSK9 market by 2034.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.